You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBrentuximab vedotin
Accession NumberDB08870
TypeBiotech
GroupsApproved
DescriptionBrentuximag vedotin or Adcetris® is an antibody-drug conjugate that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximag vedotin was approved in 2011, and in January 2012, the drug label was revised to include a boxed warning of progressive multifocal leukoencephalopathy and death following JC virus infection.
Protein structureNo structure small
Related Articles
Protein chemical formulaC6476H9930N1690O2030S40
Protein average weight150500.0 Da (range 149200-151800)
SequencesNot Available
Synonyms
cAC10-vcMMAE
External Identifiers
  • SGN-35
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adcetrisinjection, powder, lyophilized, for solution50 mg/10.5mLintravenousSeattle Genetics, Inc.2011-08-25Not applicableUs
Adcetrispowder for solution50 mgintravenousSeattle Genetics Inc2013-02-19Not applicableCanada
AdcetrisPowder for concentrate for solution for infusion50 mgIntravenous useTakeda Pharma A/S2012-10-25Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7XL5ISS668
CAS number914088-09-8
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
PharmacodynamicsBrentuximag vedotin causes apoptosis of tumor cells by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic mictrotuble network.
Mechanism of actionBrentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.
Related Articles
AbsorptionBrentuximab vedotin is administered only as an intravenous infusion so absorption is 100%.
Volume of distribution

The steady state volume of distribution is 6-10 L.

Protein bindingMMAE has a plasma protein binding range of 68-82%, and highly-protein bound drugs are not likely to displace it.
Metabolism

Only a small fraction of MMAE is metabolized primarily via oxidation by CYP3A4 and CYP3A5.

Route of eliminationMMAE is eliminated by the feces (with 72% unchanged) and urine.
Half lifeThe terminal half-life is 4-6 days.
Clearance

MMAE is cleared by the liver but not quantitative studies have been performed.

ToxicityThe most severe toxic reaction seen in patients is progressive multifocal leukoencephalopathy. Other toxicities include bone marrow suppression, infusion reactions, peripheral neuropathy, Stevens-Johnson syndrome, and tumor lysis syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous50 mg/10.5mL
Powder for concentrate for solution for infusionIntravenous use50 mg
Powder for solutionintravenous50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
References
Synthesis Reference

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24

General References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494 ]
External Links
ATC CodesL01XC12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (217 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetaminophenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.
AfatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alfentanil.
AmantadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aprepitant.
AstemizoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azithromycin.
BelimumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab.
BenzocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Brentuximab vedotin.
BexaroteneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Biperiden.
BleomycinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bleomycin.
BoceprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Brentuximab vedotin can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclosporine.
DabrafenibThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dactinomycin.
DarunavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.
DesipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.
DesloratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diclofenac.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.
DigoxinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diltiazem.
DipyridamoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.
DoxazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Brentuximab vedotin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.
EfavirenzThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etravirine.
FelodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fidaxomicin.
FingolimodBrentuximab vedotin may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluvoxamine.
FosamprenavirThe metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.
IsavuconazoniumThe serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazonium.
IsradipineThe metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide.
LevofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Methadone.
MetoprololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Midazolam.
MifepristoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.
MitomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.
NefazodoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nifedipine.
NilotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Brentuximab vedotin.
NisoldipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Brentuximab vedotin.
P-NitrophenolThe serum concentration of Brentuximab vedotin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.
PimozideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pimozide.
Platelet Activating FactorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Progesterone.
PromethazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rabies vaccine.
RanitidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine.
RifabutinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rifampicin.
RifapentineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Brentuximab vedotin.
RolapitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Brentuximab vedotin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.
SirolimusThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sirolimus.
SorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Brentuximab vedotin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Brentuximab vedotin.
TamoxifenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Brentuximab vedotin can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.
TofacitinibBrentuximab vedotin may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tolvaptan.
TrastuzumabTrastuzumab may increase the neutropenic activities of Brentuximab vedotin.
TrazodoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Troleandomycin.
VenlafaxineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.
VinblastineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinblastine.
VincristineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vincristine.
VinorelbineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Voriconazole.
ZimelidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Tumor necrosis factor-activated receptor activity
Specific Function:
Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
Gene Name:
TNFRSF8
Uniprot ID:
P28908
Molecular Weight:
63746.47 Da
References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on May 01, 2013 14:50 / Updated on August 17, 2016 12:24